Investor Ideas Potcasts #Cannabis News and Stocks on the Move: (TSXV: $KHRN.V) (NYSE: $ACB) (TSX: $ACB.TO) (TSXV: $BVO.V) (CSE: $MTEC.C) (OTCQB: $GBLX)
This month's cannabis podcasts brought to you by CLS Holdings USA, Inc. (OTCQB: $CLSH) @CLSHusa
Delta, Kelowna, BC - November 27, 2018 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its potcast site, www.potcasts.ca and its exclusive content partner, CLS Holdings USA, Inc. (OTCQB: CLSH), release today's edition of Investorideas.com potcastsCM - cannabis news and stocks to watch plus insight from thought leaders and experts.
CLS Holdings USA, Inc. (OTCQB: CLSH) is a diversified cannabis company operating as Cannabis Life Sciences an integrated cannabis producer and retailer in Nevada through its Oasis Cannabis subsidiaries with plans to expand into other States.
Listen to the podcast:
Investor Ideas Potcasts #Cannabis News and Stocks on the Move: (TSXV: $KHRN.V) (NYSE: $ACB) (TSX: $ACB.TO) (TSXV: $BVO.V) (CSE: $MTEC,C) (OTCQB: $GBLX)
Today's podcast overview/transcript:
Good afternoon, welcome to another Investorideas.com "potcast", featuring stocks to watch, cannabis news as well as insights from thought leaders and experts.
Today we will be looking at announcements from Khiron Life Sciences Corp. (TSXV: KHRN), (OTCQB: KHRNF), Aurora Cannabis Inc. (NYSE: ACB) (TSX: ACB), Bevo Agro Inc. (TSXV: BVO), Cannvas MedTech Inc. (CSE: MTEC) and GB Sciences, Inc. (OTCQB: GBLX).
Khiron Life Sciences Corp., an integrated medical cannabis company with its core operations in Colombia, announced today that the Company has received approval to commercialize and market four key products in the Company's Kuida® CBD cosmeceutical product line in Peru. This approval, from Peru's Executive Director of the Directorate of Medical Devices and Health Products of the General Directorate of Medications, Supplies and Drugs (DIGEMID) brings Kuida® product to a population of 32 Million people in Peru, and with previously announced agreements in Colombia and Mexico, positions the Kuida® brand to now be marketed to a combined population of almost 200 Million in Latin America.
Alvaro Torres, Co-founder and CEO for Khiron stated," Khiron is entirely focused on the Latin American cannabis market and meeting the needs of it's 620 million residents. With today's announcement to commercialize our Kuida® brand in Peru we expand our reach into an important new market. Peru is a region with a fast-growing cosmetic sector and an established legalized cannabis environment, which provides us with a strong foundation on which to build the Kuida® brand."
Aurora Cannabis Inc. announced today that the company has received an export request, has secured the required export permit and has now completed its first shipment of medical cannabis products to the Czech Republic, making this the 21st country in which the company operates.
The initial purchase order was placed by, and products will be shipped to Czech Medical Herbs s.r.o. ("CMH"), a Czech pharmaceutical wholesaler, who will subsequently supply pharmacies throughout the country. Czech Medical Herbs is a distributor of medicinal products with a specialization in Cannabis for medical use and medicinal products based on cannabinoids.
"This supply arrangement demonstrates our ability to enter into new jurisdictions as the partner of choice in new markets with strong barriers to entry, and is testament to the strength and business execution of our European business development team," said Neil Belot, Chief Global Business Development Officer. "The Czech Republic represents the 21st country in which we operate, and exemplifies how we are rapidly expanding our global footprint in the medical cannabis space. We look forward to building a long-term relationship with our customer, CMH, and supplying patients in the Czech Republic with our high-quality cannabis products."
Bevo Agro Inc. and Sun Pharm Investments Ltd. "Sun Pharm" announced that Zenabis has signed subscription agreements with three additional strategic investors, including two members of the ownership and management team of Hillsboro Corp Inc. ("True Buch"), for $2.1m at a subscription price of $5.00 per share for a total of 420,000 common shares. Sun Pharm agreed verbally to the price of $5.05 per share on November 16, 2018, after taking into account the exchange ratio of 0.991x. This represents a premium of $0.35 to the closing price of Bevo of $4.70 on that day. True Buch previously invested $1.0m at a subscription price of $2.82 per share for a total of 354,610 common shares, representing a total investment of $3.1m.
True Buch is a kombucha company with expertise in the creation of cultured tea beverages. True Buch cultured tea beverages are raw, unpasteurized, gluten free and non-GMO, with over 11 distinct flavours. Zenabis and TrueBuch intend to utilize each other's expertise to infuse cannabis into True Buch beverages, creating a cultured tea beverage CBD product.
"As previously announced on October 16, 2018, Zenabis and True Buch formed a significant partnership to develop and distribute CBD-based kombucha," said Rick Brar, CEO of Zenabis. "This commitment from large existing owners of True Buch shows their belief in our mission and our partnership. We believe our combined expertise in product and brand development and Kombucha brewing will result in delivery of a superior product to Canadians nationwide."
Cannvas MedTech Inc., a leading digital cannabis educator and business technology company, reported over one million cannabis consumer data points have been collected since the launch of its digital cannabis education platform. The Cannvas.Me education platform uses artificial intelligence to contextualize and adapt to its users as they navigate its education platform, ensuring a best-in-class experience while collecting valuable industry and customer data points. Cannvas Data (Cannvas MedTechs Advanced Analytics division) uses the same advanced technology to closely analyze and process data points to reveal highly focused and relevant cannabis industry insights.
"What sets us apart is our ability to truly understand the power of cannabis data due to extensive backgrounds of using data as a framework for CRM and pharma programs," said Shawn Moniz, Chief Executive Officer, Cannvas MedTech Inc. "Our team has decades of experience building these platforms in the CPG, financial and pharma industries, and we are proud to report a fantastic response to the launch of Cannvas.Me. It is clear that cannabis consumers value our independence and our unbiased physician-backed content, and with each visit we gain important consumer data that contributes to the Cannvas database. We look forward to the continued rapid growth in website traffic as we add new and dynamic education modules and sign value-added partnerships with leading cannabis companies."
GB Sciences, Inc. announced the publication of a research article co-authored by GB Sciences and key collaborators in the peer-reviewed journal Channels, which explains the potential medical benefits of using cannabinoid receptor-targeting therapies for the treatment of heart disease. GB Sciences' own Chief Science Officer, Dr. Andrea Small-Howard, joins co-authors including University of Hawaii faculty member and President of Makai Biotechnology, LLC, Dr. Alexander Stokes, and researchers from the University of Kyoto, Japan.
The link to the article as published in PubMed, the notable government source for medical studies, is found at https://www.ncbi.nlm.nih.gov/pubmed/30424709.
"People are becoming more aware that cannabinoid-based therapies can have significant medical benefits for patients, and this research study brings attention to the potential life-saving applications of cannabinoids for the treatment of heart conditions through the manipulation of specific-cannabinoid sensitive receptors," explains Dr. Andrea Small-Howard. "Our study highlights the involvement of the cannabinoid-sensitive ion channel, TRPV1, which is a newly-discovered component of signaling systems in the falling heart but it role is pivotal. Critically, our study shows, for the first time, effective reversal and remediation of this pathology with long-term administration of the drugs."
"TRPV1 is a relatively newly recognized part of the endocannabinoid system and has previously been most studied as a pain receptor", explains Dr. Alexander Stokes. "TRPV1 receptors are abundant in the heart, and our data show that if we inhibit its function with promising orally-available drugs, we can effect an exciting rescue and reversal of failing heart pathology."
In December of 2016, GB Sciences licensed patents on methods for the treatment of cardiac hypertrophy and associated pathologies through regulation of the cannabinoid receptor, TRPV1, from Dr. Stokes of Makai Biotechnology. GB remains committed to cannabis-based therapies for heart disease, as demonstrated by their filing original patent applications on the use of myrcene-based complex mixtures for heart disease in May of 2017 and another patent application on cannabinoid and terpenoid-based complex mixtures for the treatment of heart disease through manipulation of cannabis-receptors in May of 2018.
John Poss, CEO of GB Sciences says, "Heart disease is still the leading global cause of death, and cannabinoid-based therapeutics are a promising new option for its treatment. At GB Sciences, we are committed to broadening the scope of scientific research using novel applications of cannabinoid therapies and rigorously demonstrating their effectiveness."
Investor ideas reminds all listeners to read our disclaimers and disclosures on the Investorideas.com website and this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment
This podcast is sponsored by
CLS Holdings USA, Inc. (OTCQB: CLSH)
CLS Holdings USA, Inc. (CLSH) is a diversified cannabis company that, subject to receipt of certain anticipated regulatory approvals, acts as an integrated cannabis producer and retailer through its Oasis Cannabis subsidiaries in Nevada, and plans to expand to other states.
CLS stands for "Cannabis Life Sciences," in recognition of the Company's patented proprietary method of extracting various cannabinoids from the marijuana plant and converting them into products with a higher level of quality and consistency. The Company's business model includes licensing operations, processing operations, processing facilities, sale of products, brand creation and consulting services.
For additional information, please visit: http://www.clsholdingsinc.com
Subscribe to the new cannabis podcast series:
To hear more Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.
Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708
Get the cannabis/hemp stock directory as an Investor ideas member, plus get weekly updates with new pot stocks added and get the daily potcast for Investor Ideas #Potcasts #Cannabis News and Stocks on the Move. Learn more https://www.investorideas.com/membership/
About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com is a recognized news source publishing third party news and press releases plus we create original financial content. Learn about investing in stocks and sector trends from Investorideas.com with our news alerts , articles , podcasts and videos talking about cannabis, crypto, technology including AI and IoT , mining ,sports biotech, water, renewable energy and more . Investorideas.com original branded content includes the daily Crypto Corner and Podcast, Play by Play sports and stock news column, Investor Ideas #Potcasts #Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change Podcast and the AI Eye Podcast and column covering developments in AI.
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers.
Disclosure this podcast is in partnership with featured sponsor CLS Holdings USA, Inc. (OTCQB: CLSH) details :
More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp. Learn more about Investor ideas podcast and news publication services and costs https://www.investorideas.com/News-Upload/
Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: https://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.
Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.
Follow us on Social Media